Long Island scientists are growing patient 'avatars' — organoids — to test dozens of drug combinations. Early trials show promise but wider validation and faster methods are still needed.

The FTC is requiring Ascension to divest seven ambulatory surgery centers in five metros before its $3.9B AmSurg acquisition can close.

WashU neurologist Tim Miller co‑led long‑term tofersen trials that show stabilization or improvement for some SOD1‑ALS patients — a milestone for a rare genetic form. The result reflects decades of antisense work at WashU.